Ovid Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $7.3M | $566.0K | $392.0K | $1.5M | $208.4M | $12.6M | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $25.6M | $36.8M | $28.6M | $24.6M | $46.9M | $63.4M | $42.2M |
| SG&A Expense | — | $24.1M | $25.7M | $31.1M | $32.4M | $37.2M | $30.6M | $19.3M |
| Operating Income | — | $-42.4M | $-61.9M | $-59.3M | $-55.5M | $124.2M | $-81.4M | $-61.4M |
| Operating Margin | — | -585.2% | -10,933.7% | -15,122.7% | -3,696.4% | 59.6% | -645.4% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-17.4M | $-26.4M | $-52.3M | $-54.2M | $124.2M | $-81.0M | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $1.3M | $0 | $0 |
| Net Income | — | $-17.4M | $-26.4M | $-52.3M | $-54.2M | $122.8M | $-81.0M | $-60.5M |
| Net Margin | — | -240.1% | -4,670.1% | -13,351.8% | -3,604.7% | 58.9% | -642.3% | — |
| EPS (Basic) | — | — | — | $-0.74 | $-0.77 | $1.78 | $-1.39 | — |
| EPS (Diluted) | — | — | — | $-0.74 | $-0.77 | $1.76 | $-1.39 | — |
| Shares Outstanding (Basic) | 131.9M | 130.2M | 71.0M | 70.6M | 70.4M | 67.5M | 58.5M | 54.7M |
| Shares Outstanding (Diluted) | 131.9M | 130.2M | 71.0M | 70.6M | 70.4M | 68.1M | 58.5M | 54.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |